These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26820992)

  • 21. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.
    Schnurbein G; Hauke J; Wappenschmidt B; Weber-Lassalle N; Engert S; Hellebrand H; Garbes L; Becker A; Neidhardt G; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2013 Dec; 15(6):R120. PubMed ID: 24359560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors.
    Böhringer M; Obermeier K; Griner N; Waldraff D; Dickinson E; Eirich K; Schindler D; Hagen M; Jerry DJ; Wiesmüller L
    Oncogene; 2013 Nov; 32(48):5458-70. PubMed ID: 23435420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins.
    Szabova L; Gordon MB; Lu L; Pate N; Bassel L; Iacovelli AJ; Karim B; Homan PJ; Householder DB; Guerin TM; Burkett S; Day AM; Custer W; Weaver Ohler Z
    Breast Cancer Res; 2022 Nov; 24(1):75. PubMed ID: 36333737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.
    Triplett AA; Montagna C; Wagner KU
    Neoplasia; 2008 Dec; 10(12):1325-34. PubMed ID: 19048111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
    Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
    Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Citron Kinase Deficiency Leads to Chromosomal Instability and TP53-Sensitive Microcephaly.
    Bianchi FT; Tocco C; Pallavicini G; Liu Y; Vernì F; Merigliano C; Bonaccorsi S; El-Assawy N; Priano L; Gai M; Berto GE; Chiotto AM; Sgrò F; Caramello A; Tasca L; Ala U; Neri F; Oliviero S; Mauro A; Geley S; Gatti M; Di Cunto F
    Cell Rep; 2017 Feb; 18(7):1674-1686. PubMed ID: 28199840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.
    Varna M; Lehmann-Che J; Turpin E; Marangoni E; El-Bouchtaoui M; Jeanne M; Grigoriu C; Ratajczak P; Leboeuf C; Plassa LF; Ferreira I; Poupon MF; Janin A; de Thé H; Bertheau P
    Int J Cancer; 2009 Feb; 124(4):991-7. PubMed ID: 19048622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathways contributing to development of spontaneous mammary tumors in BALB/c-Trp53+/- mice.
    Yan H; Blackburn AC; McLary SC; Tao L; Roberts AL; Xavier EA; Dickinson ES; Seo JH; Arenas RB; Otis CN; Cao QJ; Lawlor RG; Osborne BA; Kittrell FS; Medina D; Jerry DJ
    Am J Pathol; 2010 Mar; 176(3):1421-32. PubMed ID: 20110418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome.
    Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ
    Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of BCCIP deficiency in mammary tumorigenesis.
    Droz-Rosario R; Lu H; Liu J; Liu NA; Ganesan S; Xia B; Haffty BG; Shen Z
    Breast Cancer Res; 2017 Oct; 19(1):115. PubMed ID: 29047390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis.
    Xu X; Qiao W; Linke SP; Cao L; Li WM; Furth PA; Harris CC; Deng CX
    Nat Genet; 2001 Jul; 28(3):266-71. PubMed ID: 11431698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation.
    Sullivan MR; Prakash R; Rawal Y; Wang W; Sung P; Radke MR; Kaufmann SH; Swisher EM; Bernstein KA; Jasin M
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice.
    Dunphy KA; Blackburn AC; Yan H; O'Connell LR; Jerry DJ
    Breast Cancer Res; 2008; 10(3):R43. PubMed ID: 18471300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
    Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
    Somyajit K; Mishra A; Jameei A; Nagaraju G
    Carcinogenesis; 2015 Jan; 36(1):13-24. PubMed ID: 25292178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.